首页BOT • ASX
add
Botanix Pharmaceuticals Ltd
市场资讯
财务信息
损益表
收入
净收入
| (AUD) | 2024年6月info | 年同比变化 |
|---|---|---|
收入 | 84.58万 | 2,753.22% |
经营支出 | 374.16万 | 90.08% |
净收入 | -420.13万 | -84.39% |
净利润率 | -496.73 | 93.54% |
每股收益 | — | — |
息税折旧摊销前利润 | -420.07万 | -86.54% |
有效税率 | — | — |
资产负债表
总资产
负债总额
| (AUD) | 2024年6月info | 年同比变化 |
|---|---|---|
现金及短期投资 | 7930.81万 | 673.71% |
总资产 | 1.12亿 | 352.83% |
负债总额 | 373.21万 | 97.99% |
权益总额 | 1.09亿 | — |
发行在外的股份 | 18.14亿 | — |
市净率 | 7.92 | — |
资产回报率 | -9.41% | — |
资本回报率 | -9.73% | — |
现金流
现金净变动
| (AUD) | 2024年6月info | 年同比变化 |
|---|---|---|
净收入 | -420.13万 | -84.39% |
来自运营的现金 | -218.35万 | 31.16% |
投资现金 | -161.19万 | -66.06% |
融资现金 | 3417.06万 | 620.67% |
现金净变动 | 3049.74万 | 3,874.53% |
自由现金流 | -277.66万 | -42.87% |
简介
Botanix Pharmaceuticals is listed on the Australian Securities Exchange with the issue code BOT. The Company is headquartered in Perth, Western Australia and Philadelphia, USA. It is a clinical stage synthetic cannabinoid company, focusing on the compound Cannabidiol. The company has two separate development platforms, dermatology and antimicrobial. Botanix also has an exclusive license to use a proprietary drug delivery system Permetrex, for direct skin delivery of active pharmaceuticals which is utilised in all of their programs. Wikipedia
成立时间
1984
员工数量
11
